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The detection of extended spectrum -lactamases (ESBL(S)) in Gram-negative bacteria that produce AmpC -lactamases is problematic. In 
the present study, the performance of modified double-disc synergy test (MDDST) that employs a combination of cefepime and 
piperacillin-tazobactam for the detection of ESBL(S) Klebsiella producing AmpC -lactamases was evaluated and compared with double-
disc synergy test (DDST). E-test phenotypic confirmatory and modified three-dimensional tests (MTDT) were adopted for more data 
confidence. A total of 100 clinical isolates of Klebsiella, which met the CLSI (2012) screening criteria as having broth microdilution 
(BMD) MIC > or =2 mg mL-1 for at least one extended-spectrum cephalosporin [ceftazidime (CAZ), cefotaxime (CTX) and cefpodoxime], 
were accurately-selected for the study. MDDST detected ESBLs in 62 out of the100 studied isolates with 100 % sensitivity and specificity, 
whereas DDST detected ESBLs in only 52 isolates with 92.9 % sensitivity and 100 % specificity. E-test could detect ESBLs in 62 isolates, 
while as many as 34/62 ESBL positive isolates were confirmed to be AmpC beta-lactamase positive by the MTDT. MDDST and E-Test 
could detect ESBLs in all the 34 AmpC positive isolates, whereas DDST detects ESBLs in only 26 isolates. The study recommended 
MDDST as superior to DDST for the detection of ESBLs in AmpC -lactamase-producing Klebsiella spp. and this was confirmed by 
MTDT and E-Tests. 
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Introduction 
Extended-spectrum -lactamases (ESBLs) are mutant, 
plasmid-mediated β-lactamases derived from older, broad-
spectrum β-lactamases and confer resistance to all extended-
spectrum cephalosporins (ESCs) and aztreonam, except 
cephamycin and carbapenem derivatives.1,2 Although 
ESBLs have been detected in Gram-negative bacteria such 
Enterobacter, Salmonella, Citrobacter, Serratia marcescens, 
Proteus spp. and Pseudomonas aeruginosa,2,3 it is most 
commonly encountered in Klebsiella spp. AmpC β-
lactamases are cephalosporinases that are poorly inhibited 
by clavulanic acid (CLA) and can be differentiated from 
ESBLs by their ability to hydrolyze cephamycins.4  A wide 
variety of Gram-negative bacteria, Klebsiella pneumonia, in 
particular, have been shown to harbor AmpC β-
lactamases.5,6  
The detection of ESBLs in AmpC-producing species of 
gram-negative bacteria is problematic. The increased 
prevalence of bacterial pathogens producing both ESBLs 
and AmpC β-lactamases creates a requirement for laboratory 
testing methods that can accurately detect the presence of 
these enzymes in clinical isolates.7 The inhibitor-based 
confirmatory test approach is most promising for isolates 
that do not co-produce an inhibitor-resistant β-lactamase like 
AmpC. However, a high-level production of AmpC may 
prevent the detection of an ESBL. This problem is 
frequently observed in tests with species or strains that 
produce a chromosomally encoded inducible AmpC β-
lactamase (e.g., Klebsiella spp., Enterobacter spp., 
Citrobacter spp., Serratia spp., Proteus spp. and 
Pseudomonas aeruginosa). Moreover, in these organisms, 
CLA may act as an inducer of high-level AmpC production 
resulting in an increase in the resistance of the isolate to 
other screening drugs, producing a false-negative result in 
the ESBL detection test. Tazobactam and Sulbactam are 
much less likely to induce AmpC β-lactamases and are, 
therefore, preferable inhibitors for ESBL detection tests with 
these organisms.8  
Another approach is to include cefepime (FEP) as an 
indicator drug.1 High-level AmpC production has a minimal 
effect on the activity of FEP, making this drug a more 
reliable detection agent for ESBLs in the presence of an 
AmpC β-lactamase.1 A test incorporating FEP and 
piperacillin-tazobactam (TZP) for the detection of 
Enterobacteriaceae that produce an extended spectrum and 
AmpC β-lactamases have been described.7  
We describe here a modified double-disc synergy test 
(MDDST), which differs from the original double-disc 
synergy test9 in two respects; first, the addition of discs of 
FEP and TZP; second, adjustment of the distances between 
various discs for accurately detecting the synergy between 
Augmentin/TZP and extended-spectrum cephalosporin. The 
test was evaluated for detecting ESBL in AmpC β-
lactamase-producing Klebsiella and compared with original 
double-disc synergy test (DDST) and phenotypic 
confirmatory test (E-test). The production of AmpC β-
lactamases in ESBL positive isolates was confirmed by the 
modified three-dimensional test (MTDT). 
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Material and Methods 
A total of 100 consecutive, non-repetitive clinical isolates 
of Klebsiella isolates was collected from a variety of clinical 
specimens, viz., urine, pus, wound swab and high vaginal 
swab, referred to the Central Microbiology Laboratory of 
Ain Shams University Hospitals for routine culture and 
sensitivity from September to December 2015. 
Screening for ESBLs -Disc diffusion method (DDM) 
The test inoculum (0.5 McFarland turbidity) was spread 
onto Mueller-Hinton agar plate, an interpretation of zone 
diameter of (CPD 17mm, CAZ ≤ 22 and CTX ≤27), this 
may indicate ESBL production (i.e.) positive screening for 
ESBL. However, FEP disc not included by CLSI (Clinical 
and Laboratory Standards Institute) for ESBL screening but 
FEP zone diameter FEP≤14mm indicate resistance which 
we considered as presumptive ESBL.10 
Detection of ESBLs-Double-disc synergy test 
The test inoculum (0.5 McFarland turbidity) was spread 
onto Mueller-Hinton agar (MHA; HiMedia) using a sterile 
cotton swab. A disc of augmentin (20 μg Amoxycillin + 10 
μg CLA) was placed on the surface of MHA; then discs of 
cefpodoxime (30 μg), CAZ (30 μg) and CTX (30 μg) were 
kept around it in such a way that each disc was at distance 
ranging between 16 and 20 mm from the augmentin disc 
(centre to centre). The plate was incubated at 37 °C 
overnight. Distances between the discs were required to be 
suitably adjusted for each strain in order to accurately detect 
the synergy. The organisms were considered to be producing 
ESBL when the zone of inhibition around any of the 
expanded-spectrum cephalosporin discs showed a clear-cut 
increase towards the Augmentin disc.9 
Modified double-disc synergy test 
The original DDST was modified for detecting ESBLs in 
AmpC-producing clinical isolates of P. mirabilis by placing 
a disc of TZP (100/10 μg) at a distance ranging between 22 
and 25 mm from FEP (30 μg) disc. Briefly, a disc of 
augmentin (20 μg amoxycillin + 10 μg CLA) was placed on 
the surface of MHA; then discs of cefpodoxime (30 μg), 
CAZ (30 μg), CTX (30 μg) and FEP (30 μg) were kept 
around it in such a way that each disc was at distance 
ranging between 16 and 20 mm from the augmentin disc 
(centre to centre), and a disc of TZP (100/10 μg) was placed 
at a distance ranging between 22 and 25 mm from the FEP 
disc. Distances between the discs were required to be 
suitably adjusted depending on the zone of inhibition 
obtained with extended-spectrum cephalosporin disc in a 
particular isolate in order to accurately detect the synergy.  
The organisms were considered to be producing ESBL 
when the zone of inhibition around FEP or any of the 
extended-spectrum cephalosporin discs showed a clear-cut 
increase towards the TZP disc. The discs of ciprofloxacin (5 
μg), amikacin (30 μg), gentamicin (10 μg) and cefoxitin (30 
μg) were also included so as to find out the susceptibility of 
the isolates to commonly used antibiotics Figure 1. 
 
 
 
 
 
 
 
 
 
 
Figure 1. Modified double-disc synergy test (MDDST) showing 
synergy between cefepime (FEP)/ceftazidime (CAZ) and 
piperacillin-tazobactam (TZP) 
Phenotypic disc confirmatory test - E-test 
This test was recommended by CLSI (E-test ESBL 
strip).10 The MIC value was read from the scale in terms of 
ug/ml where the ellipse edge intersects the strip. ESBL 
production is inferred if the MIC ratio for cephalosporin 
alone/cephalosporin plus clavulanate MIC is ≥8. ESBL 
production was also identified by the presence of a phantom 
zone or a deformation of the CAZ inhibition zone 
independent of the MIC ratios. If the MIC ratio is <8 it is 
indicative of non-ESBL production. When MIC values were 
above the test device range, the interpretation was ‘non-
determinable'.  
Detection of AmpC β-lactamases -Modified three-dimensional 
test 
The presence of AmpC β-lactamases in ESBL positive 
isolates with reduced susceptibility to cefoxitin was detected by 
MTDT.4 Briefly, fresh overnight growth from MHA was 
transferred to a reweighed sterile microcentrifuge tube. The 
tube was weighed again to determine the weight of bacterial 
mass to obtain 10-15 mg of bacterial wet weight. The bacterial 
mass was suspended in peptone water and pelleted by 
centrifugation at 3000 rpm for 15 minutes. Crude enzyme 
extract was prepared by freezing and thawing the bacterial 
pellet (five cycles). Lawn culture of E. coli ATCC 25922 was 
prepared on MHA plates, and a cefoxitin (30 μg) disc was 
placed on the surface of the medium. Linear slits (3 cm long) 
were cut using sterile surgical blade up to a point 3 mm away 
from the edge of the cefoxitin disc. Wells of 8 mm diameter 
were made on the slits at a distance 5 mm inside from the outer 
end of the slit using a sterile Pasteur pipette. The wells were 
loaded with enzyme extract in 10 μL increments until the well 
was full. Approximately 30-40 μL of extract was loaded in a 
well. The plates were incubated at 37 °C overnight. Three 
different kinds of results were recorded. Isolates that showed 
clear distortion of the zone of inhibition of cefoxitin were taken 
as AmpC producers. Isolates with no distortion were taken as 
AmpC non-producers, and isolates with minimal distortion 
were taken as intermediate strains.   
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A known AmpC-positive isolate of Klebsiella pneumoniae 
was used as control reference strain (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Modified three-dimensional test showing AmpC positive 
(A) and negative (B) results 
Results 
Sixty two/100 isolates were ESBL positive by E-test 
(golden standard test). Fifty-two out of 62 were positive by 
DDST, while MDDST detected all the 62 ESBL positive 
isolates. Sixty-seven out of 100 isolates were AmpC 
producers by M3D (golden standard test). Sixty-four out of 
67 isolates that were positive by M3D test were resistant to 
FOX with a sensitivity of 95.5 % and specificity of 63.6 % 
for detection of AmpC production with positive predictive 
value and negative predictive value of (84.2% and 87.5 %) 
respectively.  Sixty-seven out of 100 isolates were positive 
AmpC by M3D test. Thirty-four out of 67 isolates were 
positive ESBL by MDDST. On the other hand, 26/67 were 
positive by DDST. The sensitivity of DDST was 76.5 % and 
specificity of 100 % for detection of ESBL in presence of 
AmpC. Thirty-three out of 100 isolates were negative AmpC 
by M3D test. Twenty-eight out of 33 isolates were positive 
ESBL by MDDST. Twenty-six out of 33 were positive by 
double disc synergy test. The sensitivity of DDST was 
92.9 % and specificity of 100% for detection of ESBL in 
absence of AmpC in the isolates. 
This means that the sensitivity of the DDST when M3D 
was negative is better from its sensitivity when the latter 
was positive, where MDDST is positive in eight isolates 
more than double disc test in positive M3D isolates and two 
in negative M3D isolates. 
Discussion 
In our study, 62/100 isolates were positive by E-test. The 
DDST at a distance of 20mm center to center detected 52/62 
(83.9 %) ESBL positive isolates by E-test with a sensitivity 
of 83.9% and specificity of 100 %. CAZ and CTX were 
found to be the best substrates, as they revealed synergism 
with AMC in 37/62 (59.7 %) and 35/62 (56.5 %) isolates 
respectively, followed by FEP which detected 21/62 
(33.9 %). while the least detection was with CPD as it 
detected 11/62 (17.7 %). isolates. Also, Bamidele et al.16 
demonstrated that DDST using CTX, CAZ, CRO and ATM 
discs around AMC disc at a distance 15-20 mm center to 
center, on 54 isolates of P. aeruginosa collected from five 
different tertiary hospitals in Southwest Nigeria. Twenty-
nine out of 54 were resistant to two or more expanded-
spectrum cephalosporins. CRO and CTX were found to be 
the best substrate, as they revealed synergism with AMC in 
29/54 (53.7 %) and 28/54 (51.8 %) respectively. On the 
other hand, ATM and FEP showed synergism in 24/54 
(44.4 %) and 10/54 (18.6 %) isolates respectively, while 
CAZ showed the least synergy only in 9/54 (16.7 %). 
In our study 67/100 isolates were AmpC producers by the 
M3D test. Thirty-four out of 67 AmpC producers were 
ESBL positive by E- test, and MDDST while by DDST 
26/67 were ESBL positive showing 76.5 % sensitivity and 
100 % specificity for detection of ESBL in the presence of 
AmpC. On the other hand, 26/33 (78.8 %) non-AmpC 
producers were positive by DDST Showing 92.9 % 
sensitivity and 100 % specificity of detection of ESBL in 
absence of AmpC. While, MDDST showed 100 % 
sensitivity and specificity in detection of ESBL in the 
presence and absence of AmpC as it identified the 10 
isolates, which were not detected by DDST where MDDST 
was positive in eight AmpC producer isolates and the two 
AmpC negative isolates (i.e. all 62 ESBL positive isolates).  
Similarly, Dhara et al.15 demonstrated that 44/54 
Klebsiella isolates collected from a blood culture from 
neonatal intensive care unit (NICU) patients referred to 
microbiology lab of B.J. Medical College, at Ahmedabad in 
India, were ESBL positive isolates by PCDDT and 
coproduce AmpC enzyme which was confirmed by the 
M3D test. MDDST detected the all 44 (100 %) ESBL 
positive isolates. Thus MDDST showed 100 % sensitivity 
and specificity for detection of ESBL in the presence of 
AmpC compared to the standard test DDST which detected 
36/44 ESBL positive isolates.  
In our study, 64/67 M3D-positive isolates were resistant to 
FOX with a sensitivity of (95.5 %) and a specificity of 
(63.6 %) in the detection of AmpC production. While 12/33 
(36.4 %) M3D test negative was FOX resistant. While FOX 
susceptibility in three out of 67 (4.5 %) M3D-positive 
isolates may be explained by Peter-Getzlaff et al.14 who 
stated that strains carrying ACC gene may appear FOX 
susceptible. 
Conclusion 
Double disc synergy test may be used for detection of 
ESBL in the isolates which produce only ESBL and not for 
detection of ESBL in isolates coproducing AmpC enzyme 
like Enterobacter, Serratia, Citrobacter and also with 
Klebsiella spp.  
Modified double disc synergy test using TZP and FEP at a 
distance 20mm center to center may serve as a reliable 
confirmatory test for detection of ESBLs in AmpC positive 
isolates instead of DDST.  
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